Immunotherapy is becoming increasingly important in the management of urological, gynecological, and gastrointestinal cancers. Immune checkpoint inhibitor-based combinations have become a standard of care for patients with metastatic renal and liver cancers, as well as for many patients with bladder, cervical, gastric, and esophageal cancers, based on various biomarkers. Some tumor types are less responsive to immunotherapy, such as prostate and colon cancer. In these tumors, however, a subgroup of patients with a microsatellite-instability-high/DNA-mismatch repair deficient molecular phenotype significantly benefits from immunotherapy. Molecular characterization is therefore essential to identify patients who may benefit from these treatments. One of the major challenges is the search for new predictive biomarkers and novel combinations or strategies to further improve patient outcome.
Keywords: Immuncheckpoint-Inhibitoren; Immunotherapy; Immunothérapie; Immuntherapie; Krebserkrankungen des Verdauungstrakts; cancers digestifs; cancers gynécologiques; cancers urologiques; gastrointestinal cancers; gynecological cancers; gynäkologische Krebserkrankungen; immune-checkpoint inhibitors; inhibiteurs des checkpoints immunitaires; urological cancers; urologische Tumoren.